Dr. Perl Discusses Upcoming CAR T-Cell Therapies for ALL

Video

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses upcoming chimeric antigen receptor (CAR) T-cell therapies for patients with acute lymphoblastic leukemia (ALL).

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses upcoming chimeric antigen receptor (CAR) T-cell therapies for patients with acute lymphoblastic leukemia (ALL).

There has been interest in patients who lose response to CAR T-cell therapy, says Perl. One mechanism of resistance has been the loss of expression of the target of the CAR T cells. Many of those patients lack CD19, which has been the target of the cells that were generated.

Investigators have begun investigating whether 2 CAR T cells are needed, one directed against an antigen like CD19, the other against a second antigen, or whether a fallback option for the cells that do grow despite the T-cell therapy be better? Early data have looked at CD22, which is also commonly expressed in patients with ALL, but they are not as far along as data with CD19.

The development of CAR T-cell therapy has been particularly interesting in myeloma, says Perl. There has been some development of CAR T cells targeting CD19, but B-cell maturation agent (BCMA) has been the main area of development.

Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
© 2025 MJH Life Sciences

All rights reserved.